drugset
drugset / Trial / NCT06117514

Sudapyridine (WX-081) in Healthy Volunteers

NCT06117514 ↗

Phase 1 Completed 82 enrolled Shanghai Jiatan Pharmatech Co., Ltd
RandomizedParallel-groupDouble-blindTreatment

Summary

The objective of this study is to evaluate the safety, tolerability as well as pharmacokinetics of Sudapyridine (WX-081) in Chinese volunteers.

Timeline

Start
2019-02-13
Primary completion
2020-07-02
Completion
2020-07-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Sudapyridine Small molecule 30 mg Oral
Subject Sudapyridine Small molecule 100 mg Oral
Subject Sudapyridine Small molecule 200 mg Oral
Subject Sudapyridine Small molecule 300 mg Oral

Indications

No indication recorded.